Ma Wenhui, Yang Lu, Zhang Yu, Gao Yuan, Jie Huan, Huang Cong
Department of Radiology, No. 926 Hospital, Joint Logistics Support Force of PLA, Kaiyuan, Yunnan, 661699, People's Republic of China.
Department of Oncology, No. 926 Hospital, Joint Logistics Support Force of PLA, Kaiyuan, Yunnan, 661699, People's Republic of China.
Breast Cancer (Dove Med Press). 2025 Jul 8;17:573-581. doi: 10.2147/BCTT.S530834. eCollection 2025.
The heterogeneity of the tumor microenvironment (TME) in breast cancer significantly influences therapeutic response and prognosis, yet noninvasive evaluation remains a clinical challenge. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), through multiparametric quantitative analysis (eg, K, V, K), enables dynamic characterization of tumor vascularization and perfusion heterogeneity. Concurrently, radiomics technology, leveraging high-throughput feature extraction and machine learning modeling, identifies potential biomarkers associated with TME biological properties. This review systematically examines the integration strategies of DCE-MRI multiparametric quantification and radiomics: first, elucidating the capability of DCE-MRI pharmacokinetic models to quantify microvascular heterogeneity, and delineating radiomics feature screening and predictive model construction based on 3D segmentation. Furthermore, it explores the combined application of these techniques in evaluating angiogenesis, resolving immune microenvironment dynamics, and mapping metabolic heterogeneity, with emphasis on clinical translational evidence in molecular subtype discrimination, treatment response prediction, and prognostic assessment. Key limitations persist in technical standardization (eg, 37% variability in Ktrans values across 1.5T/3.0T systems) and biological interpretability, with fewer than 40% of radiomics features linked to known molecular pathways. Future advancements demand multicenter data harmonization, radiogenomics integration, and digital twin technology to optimize personalized therapeutic navigation systems. This work provides methodological insights and technical innovation pathways for noninvasive TME heterogeneity assessment in breast cancer.
乳腺癌肿瘤微环境(TME)的异质性显著影响治疗反应和预后,但无创评估仍是一项临床挑战。动态对比增强磁共振成像(DCE-MRI)通过多参数定量分析(如K、V、K),能够动态表征肿瘤血管生成和灌注异质性。同时,放射组学技术利用高通量特征提取和机器学习建模,识别与TME生物学特性相关的潜在生物标志物。本综述系统地研究了DCE-MRI多参数定量与放射组学的整合策略:首先,阐明DCE-MRI药代动力学模型量化微血管异质性的能力,并基于三维分割描述放射组学特征筛选和预测模型构建。此外,探讨了这些技术在评估血管生成、解析免疫微环境动态以及描绘代谢异质性方面的联合应用,重点关注分子亚型鉴别、治疗反应预测和预后评估中的临床转化证据。关键局限性仍然存在于技术标准化(例如,1.5T/3.0T系统间Ktrans值的变异性为37%)和生物学可解释性方面,与已知分子途径相关的放射组学特征不到40%。未来的进展需要多中心数据协调、放射基因组学整合和数字孪生技术来优化个性化治疗导航系统。这项工作为乳腺癌无创TME异质性评估提供了方法学见解和技术创新途径。